Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 132.08M | 124.61M | 121.80M | 138.26M | 134.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.08M | 124.61M | 121.80M | 138.26M | 134.52M |
| Cost of Revenue | 105.09M | 101.37M | 102.07M | 109.52M | 104.90M |
| Gross Profit | 26.99M | 23.24M | 19.72M | 28.74M | 29.62M |
| SG&A Expenses | 10.93M | 10.61M | 14.37M | 10.32M | 10.38M |
| Depreciation & Amortization | 3.72M | 3.83M | 3.76M | 3.67M | 3.59M |
| Other Operating Expenses | -173.00K | -368.00K | -380.00K | -358.00K | -375.00K |
| Total Operating Expenses | 119.57M | 115.44M | 119.83M | 123.15M | 118.50M |
| Operating Income | 12.51M | 9.17M | 1.97M | 15.11M | 16.03M |
| Income Before Tax | 9.28M | 6.31M | -1.00M | 13.22M | 18.28M |
| Income Tax Expenses | 3.82M | 507.00K | -251.00K | 8.09M | 3.75M |
| Earnings from Continuing Operations | 5.46M | 5.80M | -753.00K | 5.13M | 14.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -19.00K | 158.00K | -36.00K | -181.00K | -285.00K |
| Net Income | 5.44M | 5.96M | -789.00K | 4.95M | 14.24M |
| EBIT | 12.51M | 9.17M | 1.97M | 15.11M | 16.03M |
| EBITDA | 16.23M | 13.00M | 5.74M | 18.78M | 19.62M |
| EPS Basic | 0.12 | 0.13 | -0.02 | 0.11 | 0.31 |
| Normalized Basic EPS | 0.12 | 0.08 | -0.02 | 0.16 | 0.17 |
| EPS Diluted | 0.12 | 0.13 | -0.02 | 0.11 | 0.30 |
| Normalized Diluted EPS | 0.12 | 0.08 | -0.02 | 0.16 | 0.16 |
| Average Basic Shares Outstanding | 45.87M | 46.03M | 46.07M | 46.70M | 46.26M |
| Average Diluted Shares Outstanding | 46.71M | 46.88M | 46.07M | 46.70M | 47.08M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 8.43% | 7.72% | -58.30% | 9.42% | 3.27% |